BriaCell Therapeutics Corp., a biotechnology company focused on immuno-oncology, is making strides in the development of new cancer therapies. With their lead drug candidate, Bria-IMT, currently in Phase I/IIa clinical trials alongside immunotherapy development candidates retifanlimab, they are moving closer to finding effective cancer treatments. Additionally, BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic tool used to determine patients' HLA types. The company has also formed strategic partnerships with Incyte Corporation and the National Cancer Institute to further its research and development efforts. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.